ENTEROFLORID

Active agents(INN):
A complex of eubiotic microbes of the components of normal gut microflora: Bifidobacterium bifidum I, Bifidobacterium longum; Lactobacillus acidophilus; Lactobacillus fermentum, Lactobacillus Plantarum; E-Coli M-17; Enterococcus faecium.

Pharmaceutical form: capsules for oral administration

Formulation:
1 capsule of the drug contains:
Active moiety: a total of not less than 100 million (108) live probiotic microbes including Bifidus bacteria not less than 10 million (107), lactic bacteria not less than 107, the enteric bacterium E. coli E-Coli M-17 not less than 107 and Enterococcus faecium not less than - 107

Excipients: inulin, fructooligosaccharide (FOS), lactose and starch.

Description: Gelatine capsules, size 01 white bovine
Pharmacological group: Modifier of gut microflora - eubiotic.
ATC-code: A07FA

Pharmacological properties:
The therapeutic effect of Enteroflorid is due to the antagonistic effect of the microbial cells of the drug in relation to pathogenic and opportunistic pathogen intestinal microorganisms. A high quantitative level of normal gut microflora and its predominance in microbiocenosis achieved with Enteroflorid normalizes the activity of the gastrointestinal tract, improves metabolic processes, prevents the formation of acute forms of intestinal diseases, and increases the nonspecific resistance of the body.

The biologically active food supplements FOS and inulin, which are formulated into the drug, enter unchanged in the lower part of the gastrointestinal tract, namely in the colon, where they are additional substrates for the microbes that are components of the drug and potentiate their growth. They also have a positive effect on intestinal motility.

Indications for use:
Enteroflorid is intended for the treatment of adults and children over three years of age suffering from the following diseases of the gastrointestinal tract:
Dysbacteriosis of various etiologies, including those resulting from the use of antibiotics and May and Baker;
Acute and chronic gastroenterocolitis;
Intestinal dysfunction or the release of pathogenic and opportunistic microorganisms;
Reconvalescence period in patients after acute intestinal diseases.

Dosage and Administration:
Enteroflorid is taken orally, 20-30 minutes before a meal, taking the capsule with a small amount of boiled water at room temperature.
Adults have prescribed 3-4 capsules per day, for children from 3 to 12 years old - 2 capsules per day.
When prescribing the drug to infants, the contents of the capsule are dissolved in 1-2 teaspoons of boiled water at room temperature and thoroughly mixed. Children take the mixture with a small amount of sweetened water or cool tea.
The duration of treatment with Enteroflorid is determined by the severity of the clinical signs of the disease, the age of the patient and is 2-4 weeks.
For preventive purposes, depending on age, from 1-2 capsules per day are prescribed for 5-10 days.

Side effects:
In the first days of taking the drug, a gradually disappearing increase in meteorism is possible.

Contraindications:
There are no contraindications.

Drug interactions:
There are no undesirable effects when interacting with other drugs.

Incompatibility: No data.

Special warnings:
Use with caution in patients with lactase deficiency.

Pregnancy and lactation:
There are no contraindications.

Impact on the ability to drive vehicles and control mechanisms:
Does not affect.
The drug should be stored in a place inaccessible to children and not used after the expiration date.

Overdose:
There is no evidence of a possible overdose.

Drug form:
A blister pack of 10 capsules along with instructions for use in a cardboard box.

Storage conditions:
In a dry, dark place, at a temperature no higher than + 250C.

Shelf life: 2 years

Conditions of release: Out of prescription.